Synteract focusing on specific therapeutic areas as it eyes market growth

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/showcake)
(Image: iStock/showcake)
The contract research organization (CRO) Synteract today announced the creation of “therapeutic centers of development” as it looks to deepen its footprint in the mid-size CRO market space.

According to the company, the centers of development will include oncology – especially immunotherapy studies – pediatrics, neuro-degenerative disorders, as well as rare and orphan diseases.

"Our centers of therapeutic development are areas of specific focus where we have a lot of experience,"​ Synteract CEO Steve Powell told us. 

The CRO will continue to support other therapeutic areas where clients have needs, he explained; "However, by more clearly defining our areas of ​specialization we have an opportunity to make it easier to answer 'Why Synteract?'"

Echoing this sentiment in the press release, chief commercial officer Jack Shannon said that by “more clearly delineating”​ the company’s attention on “these growing development areas”​ it will have “a real opportunity”​ to expand its presence in the mid-market space​.

The new position was created in collaboration with its customers and internal teams, according to the company. 

Related news

Show more

Related products

show more

Next generation ePRO from SQN Health

Next generation ePRO from SQN Health

In an era of rapid technology growth, healthcare requires low cost solutions for real-time data collection. We have come a long way from paper to EDC and...

baxter_bloomington_facility_larger

Sterile Injectables Contract Manufacturing

Baxter BioPharma Solutions | 02-Apr-2018 | Product Brochure

Baxter BioPharma Solutions' award-winning facility in Bloomington, Indiana, USA, is a leader in sterile contract manufacturing of injectable products.

Related suppliers

Follow us

Products

View more